ABSTRACT
INTRODUCTION
Diabetes mellitus currently affects approximately 415 million people worldwide [1] . It is estimated the global health expenditure on diabetes is approximately $673billion; indeed in the USA alone the cost is approximately $320 billion. Of this cost, however, only 12% is spent Enhanced content To view enhanced content for this article go to www.medengine.com/Redeem/ 2984F0604272C927. on directly managing the diabetes itself, with the majority of the expenditure being on the complications of the disease [2] . Cardiovascular disease is the most common cause of death and disability among people with diabetes; the diagnosis conferring a twofold excess risk of cardiovascular disease, independent of the usually accompanying adverse lipid and weight profile [3] . Therefore, reducing the cardiovascular risk of people with diabetes has been at the forefront of diabetes research with the intention of improving the health and wellbeing of the population whilst simultaneously reducing the global financial burden of the disease. At the core of cardiovascular protection, good blood pressure control, weight reduction, improved physical activity and appropriate statin usage have been demonstrated to substantially reduce event rate [4] .
Diabetes is diagnosed and characterized by hyperglycemia, and thus for many years, strict glycemic control was thought to be key to improving cardiovascular events. Whereas tight glycemic control unequivocally improves microvascular outcomes, the benefit has not been consistently demonstrated in the macrovasculature [5] [6] [7] . Multiple explanations have been presented for this lack of benefit, or in the case of the ACCORD study (ClinicalTrials.gov identifier, NCT00000620) the apparent harm [6] . There is still no unifying accepted theory. Many have suggested the predominantly insulinocentric approach to the management of glucose may have contributed to the lack of benefit [8] as these therapies are associated with significant weight gain [9] and risk of hypoglycemia [10] .
Although unlikely to account for the complete lack of benefit seen in these studies it is generally accepted that these recognized complications of treatment mitigate the benefit of good glycemic control. Indeed, the 2.7-fold excess cardiovascular mortality reported in the systematic review and meta-analysis of observational studies was in part attributed to these complications of treatment [11] . Liraglutide also shows marked anti-oxidative, anti-inflammatory, and anti-apoptotic effects on HUVECs exposed to tumor necrosis factor alpha (TNFa) [17] , and attenuates the accompanying endothelial cell dysfunction [18] . Additionally, liraglutide reduced hyperglycemia-induced endoplasmic reticulum stress in HUVECs via mitochondrial fusion processes, thereby reducing apoptosis [19] .
Interestingly this effect may be a direct mitochondrial effect rather than a GLP-1 receptor-mediated effect. Exenatide, however, failed to protect rat femoral arterial ring endothelial cells from triglyceride-induced cellular dysfunction [20] .
In the animal models GLP-1 also appears to have favorable effects on vascular function, independent of its glucose lowering effects. GLP-1 administration mediates endothelial-dependent relaxation in the rat pulmonary artery [21, 22] , which was attenuated in the presence of a nitric oxide synthase antagonist suggesting the involvement of nitric oxide (NO) in mediating its vascular effects. This is supported by observations that GLP-1 promotes NO-dependent relaxation of mouse mesenteric arteries [23] . The GLP-1 vascular effect appears to vary by vascular bed, causing endothelial-independent relaxation, via the GLP-1 receptor, in femoral arteries [24] but having no impact on rat aorta isolates [21] . GLP-1 is also protective against ischemia-reperfusion injury in isolated rat hearts [23, [25] [26] [27] [28] and has renoprotective (reducing proteinuria and microalbuminuria) effects, in addition to the cardioprotective effects in Dahl salt-sensitive hypertensive rats [29] . Whether these effects are mediated directly via the GLP-1 receptor is unclear, as the vasodilatory effects have been observed to be both dependent [24] and independent [23] of the GLP-1 receptor. In the latter of these studies, GLP-1(9-36), which is the product from the degradation of GLP-1 by DPP-4, mediated relaxation of mouse mesenteric arteries [23] . Thus, it is clearly evident that GLP-1 acts as a vasodilator in animal models potentially having cardioprotective properties, although whether this is dependent on GLP-1 receptor or another mechanism remains to be elucidated.
Early work in humans replicated these findings. Acute administration of GLP-1 increased flow-mediated dilatation (endothelial dependent) in type 2 diabetic male subjects with coronary artery disease but had no significant effect on young healthy, lean male subjects in whom no existing failure of endogenous GLP-1 activity would be anticipated [30] . In a broader general population sample aged 18-50 years, GLP-1 did improve forearm blood flow by approximately 30% and augmented endothelial-dependent forearm blood flow response to acetylcholine by up to 40% [31] .
Conversely, endothelial-independent function was not influenced by the acute administration of GLP-1 in either diabetic or healthy individuals suggesting GLP-1 improves function rather than structure [30, 31] . GLP-1 infusions were also shown to improve regional and global left ventricular function when administered within 6 h of an acute myocardial infarction and improve systolic function after successful primary angioplasty in those with severe left ventricular dysfunction [32] .
Observations from early clinical trials suggested these benefits would extend into improvements in cardiovascular outcomes. A meta-analysis of the GLP-1 receptor agonist use demonstrated a reduction in blood pressure of 3.6/1.4 mmHg, weight of 2.9 kg and total cholesterol of 0.1 mmol/L [33] . A retrospective analysis of obese people with type 2 diabetes suggested an improvement in both blood pressure and C-reactive protein with the exendin-4-based GLP-1 Receptor agonist, exenatide [34] . A meta-analysis of the prospective liraglutide effect and action in diabetes (LEAD) studies, the registration program for the GLP-1 analog, liraglutide, demonstrated improvements in lipid profile, B-type natriuretic peptide, high-sensitivity C-reactive protein and plasminogen activator inhibitor-1 all of which have been associated with cardiovascular outcomes [35] . These benefits have also been demonstrated with exenatide and the DPP-4 inhibitor sitagliptin, suggesting this is a class effect [36, 37] .
Reductions in postprandial triglycerides and apoB48, again both tightly associated with cardiovascular risk, have been demonstrated with both the DPP-4 inhibitor, vildagliptin [38] , and the GLP-1 analog, liraglutide [39] .
CARDIOVASCULAR OUTCOME DATA
During pre-clinical investigation of incretin therapies, most trials record and adjudicate cardiovascular events. Although differing in protocols, the standardized recording and reporting of major adverse cardiac events (MACE) allows for meaningful meta-analyses.
In a meta-analysis of 25 trials lasting [6 months and reporting at least one cardiovascular event,
GLP-1 receptor agonists demonstrated a significant 49% reduction in MACE (p\0.03) compared to placebo and a trend towards a 22% improvement versus active comparator. This failed to reach statistical significance due to the small numbers of events, short-term nature of the studies and the low-risk nature of the participants [40] . A similar benefit was seen in DPP-4 inhibitor trials, although with 70 trials to analyze, the 29% reduction in MACE was highly significant [41] . Again this analysis was limited by the relatively short duration of the studies and the relatively pure and healthy populations that were studied in these regulatory trials.
Since the concern over rosiglitazone potentially increasing cardiovascular events Of these studies, the result that generated most attention was the post hoc analysis of the non-adjudicated outcome for admissions due to heart failure in the SAVOR-TIMI study. In the first 6 months of the study there was an increase of 0.7% in hospitalization due to heart failure, which amounted to a 27% relative risk increase [45] .
Despite the fact these were non-adjudicated outcomes in patients with pre-existing heart failure, the highly significant increase in events raised considerable concerns.
As a result, existing studies were required to perform an analysis of heart failure admissions.
The EXAMINE study showed a similar trend of 19% increase in admissions, although due to small numbers this did not reach significance [46] . TECOS, reassuringly, showed no increase in heart failure signal with an HR of 1.0 (95% CI 
WHAT CAUSES THE DISCONNECT BETWEEN THE EARLY CLINICAL WORK AND THE RANDOMIZED CONTROLLED TRIALS?
There has been much deliberation as to why the potential benefit promised in the pre-clinical and early clinical work has not been realized in the definitive randomized controlled trials. One hypothesis explores the possibility that this may be simply due to the duration of the studies. Indeed, if the heart protection study (HPS) or the Scandinavian simvastatin survival study (4S) had been censored at 18 months or 2 years they would have not demonstrated any benefit from simvastatin [48, 49] , yet statin therapy is widely accepted as a core element of cardiovascular risk reduction. If this is the case, studies such as the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER, ClinicalTrials.gov identifier, NCT01179048) [50] and the cardiovascular outcome trial of linagliptin versus glimepiride in type 2 diabetes (CAROLINA, ClinicalTrials.gov identifier, NCT01243424) [51] trials that have a study minimum duration of 3.5 years (the point at which the HPS curves were clearly diverged) should show benefit. The reduction in cardiovascular events suggested by the early meta-analyses, however, was present in studies with a mean duration of 44.1 weeks [41] . Thus, duration of exposure to agents may not be the only factor. Another significant difference between the regulatory studies that contributed to the meta-analyses and the subsequent cardiovascular outcome trials is the duration of diabetes in those studied. Regulatory studies tend to be performed in otherwise well participants, early in diabetes. Complex multi-morbid patients, such as those enrolled in TECOS, EXAMINE, SAVOR-TIMI and ELIXA are rarely used in these studies to minimize inter-participant variability and maximize the ability to detect differences. Event driven cardiovascular outcome trials, however, prefer high-risk patients to maximize the event rate and increase study power. This necessitates a longer duration of diabetes and multi-morbidity driven polypharmacy.
To date, the only trial to demonstrate cardiovascular benefit from glycemic control is the UKPDS (ClinicalTrials.gov identifier, NCT01099865) [5] , which took newly diagnosed people with diabetes. The subsequent glycemic control trials, ACCORD, ADVANCE (ClinicalTrials.gov number, NCT00145925) and VADT (ClinicalTrials.gov identifier, NCT00032487) failed to demonstrate benefit [6, 7, 52, 53] . The failure to achieve benefit in these studies has been attributed to existing bad legacy effect from the preceding Deacetylation of the SIRT-1 gene and tumor suppressor p53 occurs [56] . These have both been demonstrated to control p66 SHC transcription [57, 58] . Thus, the epigenetic changes in the SIRT-1 and p53 genes may perpetuate the original hyperglycemic effects. Interestingly metformin has been demonstrated to reverse the effects of SIRT-1 [59] , in keeping with the observed benefit in UKPDS whereby metformin was substantially superior to sulphonylurea and insulin-based therapy [60] . If the failure of benefit in the existing trials is attributable to this, the vildagliptin efficacy in combination with metformin for early treatment of type 2 diabetes (VERIFY, ClinicalTrials.gov identifier, NCT01528254), which is taking newly diagnosed people with diabetes and randomizing them to receive either immediate DPP-4 combination with metformin or metformin alone, may demonstrate a benefit. Unfortunately, the primary endpoint of this study; time to initial treatment failure rate and rate of loss in glycemic control over time, may result in the study being terminated before being able to demonstrate a cardiovascular benefit.
Finally, these complex multi-morbid patients are characterized by polypharmacy, whereas regulatory trials are usually performed with as few concomitant prescriptions as possible. It is known that glibenclamide, and to a lesser extent glimepiride, attenuates the vascular benefit of GLP-1 [31] . This is most likely mediated through effects on mitochondrial ATP-sensitive potassium (K ATP ase) channels. These K ATP ase channels are also responsible for myocardial ischaemic preconditioning, and their inhibition by sulphonylurea use has been attributed, at least in part, to the historic poorer prognosis after myocardial infarction of those with diabetes [61] . This interaction between sulphonylurea and GLP-1 is well established, however, is not accounted for in any of the existing studies with the exception of CAROLINA, comparing DPP-4 inhibitor to sulphonylurea [51] . 
